The search for an HIV vaccine by Makgoba, MW et al.
THE SOU1HERN AFRICAN JOURNAL OF HIV MEDICINE ------------ MARCH 2002
CLINICAL REVIEW
Malegapuru William Makgoba, Nandipha Solomon, Timothy Johan Paul Tucker
Medical Research Council of South Africa, Tygerberg, W Cape
POTENTIAL DEVELOPMENTS
If we fail to provide the world with an effective HJV vaccine,
future generations will judge us harshly, because this failure will
be due not to lack of ability or resources but to politics
POUTICS
Successful vaccine development entails adequate investment in
the countries that carry the burden of the HIV/AIDS pandemic
Equitable public-private partnerships between researchers,
manufacturers, and distributors and partnerships between rich
and poor countries are the best strategy for the development of
the vaccine
An effective, affordable, and accessible HIV vaccine is within
reach
Many political realities will need to be accepted if the
global health community is to develop an HIV vaccine:
• Vaccines are a public good and should be supported
worldwide.
• Rich countries have the expertise and experience to
develop and test HIV vaccines but do not have
sufficient numbers of patients to conduct clinical trials
of efficacy.
• Most poor countries have poor infrastructure and
inadequate resources to conduct major trials of an HIV
vaccine but are fertile ground for such trials. Thus, rich
and poor nations are obliged to co-operate in the
successful development of an HIV vaccine.
• Any trial of an HIV vaccine must take into account the
history of exploitation and abuse of vulnerable people
in clinical trials. All research has the potential to
introduce unequal power relations between the
researchers and the trial participants, particularly when
the researchers are from a rich nation and the
participants are from a poor nation.
• Rich countries want to do research in poor countries.
Poor countries often have weak research infrastructure
and regulatory institutions, allowing rich countries to
exert more control over the research and over
intellectual property rights.
• Most countries lack the political will and commitment
- reflected in inadequate investment - to develop an
HIV vaccine.
Will AN APPROPRIATE HIV VAWNE EVER BE
DEVELOPED?
THE SEARCH FORAN HIVVACCINE
This article appeared in the BMJ of 26 January 2002
(324: 211 -213), and is reproduced with permission from
the BMJ publishing group.
The answer to this depends on a complex interplay of
politics, science, institutions and their organisation, and
public-private partnerships.
HIV infections and deaths from AIDS continue to ravage
many countries around the world, with most infected
people living in the poorest nations.' In terms of morbidity
and mortality, the HIV!AIDS pandemic is worse than the
Black Death of the 14th century. The search for an HIV
vaccine was seen as the logical solution to the burgeoning
epidemic soon after the discovery of HIV, but early
enthusiasm became muted as the realities of the challenge
became evident'"
Nevertheless, there are scientific reasons why there is hope
that an HIV vaccine will ultimately be developed. Firstly,
studies of non-human primates that were given candidate
vaccines based on HIV or SIV (simian immunodeficiency
virus) have shown either complete or partial protection
against infection with the wild type virus." Secondly,
successful vaccines have been developed against other
retroviruses.' Thirdly, almost all humans develop some form
of immune response to HIV infection, with some exposed
people remaining uninfected or developing immune
responses that are protective or that are able to control the
viral infection over long periods.' Some people have
remained free of disease for up to 20 years, often with
undetectable viral loads"" A group of sex workers from
Nairobi and South Africa has remained HIV-negative
despite continuing high-risk exposure; resistance to HIV
infection in these people is thought to be due to their
ability to mount protective immune responses to HIV,
rather than to any innate host genetic factors.···" This
group has provided insights into strategies for developing
avaccine.
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SCIENCE
The current impressive knowledge of the genotypic,
phenotypic, pathological and clinical aspects of HIV!AIDS
reflects the substantial scientific discourse that has
occurred around the world over the past two decades.
However, the current knowledge base remains inadequate,
in that it has failed to elucidate the most critical item on
the HIV vaccinologist's wish list: the correlates of
protection against HIV. Until these are defined with
accuracy, as has been the case with other infectious agents,
such as hepatitis B, the required 'height of the high jump
bar' will remain speculative.
Another problem is that animal models for investigating
candidate vaccines are inadequate. Results from studies of
candidate vaccines in small animal models are invaluable,
but their applicability to the development of an HIV vaccine
in humans may be tenuous. Products that have an
acceptable safety record in animal studies should be used
as rapidly as possible in human studies, because human
studies will give critical insights into the potential success
or failure of a vaccine that far outweigh those from any
animal data.
INSTITUTIONS
Science has traditionally moved relatively slowly and
cautiously in the transition from laboratory development of
new agents to commercialisation. Vet in the case of HIV
vaccines the scientific community is, for humanitarian
reasons, under pressure to move with urgency. The
scientific and corporate communities are being asked to
'think out of the box' and to break down traditional modes
of operations, while still maintaining the highest values of
science and ethics, in developing an HIV vaccine.
For almost a decade after the discovery of HIV a concerted
and co-ordinated international effort to produce a vaccine
was slow to develop. But a number of initiatives have
helped to create a scientific framework for rapidly testing
hypotheses and products. The International AIDS Vaccine
Initiative [IAVI), whose mission is the development of and
worldwide access to an HIV vaccine, has helped to keep the
need for a vaccine high on the agendas of many
governments. Following from IAVI's advocacy, changes in
the scientific priorities of traditional institutions, such as
the National Institutes of Health, the WHO, and the
European Union's HIV vaccine platform, have also helped,
as has the establishment of regional vaccine development
programmes in poor countries, such as the South African
AIDS Vaccine Initiative.
This new framework gives the public and private sectors
the chance to become partners in getting important
academic, financial, and logistic support. Effective co-
ordination, maintenance, and expansion of these structures
are essential. Equally important is the need for co-
operation among these international bodies, to ensure that
the efforts are not inhibited by organisational pride,
traditions, or the desire to be first.
levels of political will to support global initiatives to
develop an HIV vaccine will largely determine the rate of
their progress and success. Such political support will need
to come from the highest levels of government and from
global bodies such as the United Nations. Vaccines are but
a part of the message of prevention that all governments
should be endorsing, along with progressive policies on sex
education, condom distribution, needle exchange
programmes, and appropriate treatment. State and private
sector funding of national and international vaccine
programmes should be given the highest priority.
Political support for these programmes needs to be
independent of other international crises. For example, our
response to the events of 11 September should not deflect
attention from the urgent need to develop a vaccine
against the greatest threat ever to humanity from an
infectious disease. Vet compare the rapid and committed
response by the US government to the threat of anthrax
with many governments' lack of support for development
of an HIV vaccine over the past two decades.
PUBLIC-PRIVATE PARTNERSHIPS
Political processes should seek to maximise the synergies
between government and the private sector through
public-private partnerships. Over decades the private sector
has been the mainstay of vaccine production and
distribution, and thus the private sector's expertise needs to
be harnessed to produce and distribute an appropriate HIV
vaccme.
Vaccines have never been as commercially successful as
other medical treatments, and so entering the field of HIV
vaccine development is a risk for companies. Most of the
initial uptake of an effective vaccine will have to be in
countries with a high prevalence; and as these countries
are heavily indebted, they will not have the resources to
buy and distribute the vaccine. Governments of the rich
countries will have to work with IAVI, the World Bank, the
United Nations, the WHO, and the private sector to ensure
that commercial guarantees are in place to give the private
sector an incentive to move into this field. These
commercial agreements will have to give attention to:
• Setting limits on exploitation of intellectual property
• 'Guaranteed' markets
• Price controls in poor countries
• limiting liability in the event of a small number of
adverse events [such as with polio), and
• Ways to increase global manufacturing capacity.
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Equally important will be the need for all countries,
irrespective of wealth, to develop strategies to incorporate
HIV vaccines into national vaccination programmes.
WHAT WILL WE DO WITH AN HIV VACCINE?
TARGET POPULATIONS
Even when we do develop an HIV vaccine, there is no
guarantee that it will be used appropriately. This is why we
should determine the rules for access to and distribution of
the vaccine before making it widely available. The rules for
distribution of an HIV vaccine must break with the present
rules for access to new drugs and vaccines whereby priority
is given to wealthy nations and people, who do not bear the
burden of this disease. We see this problem in the current
unequal access to antiretroviral drugs. HIV vaccines must
be given firstly to the poorest and most vulnerable people
in our global society. This will be adifficult challenge, as our
current experience with polio vaccines in poor countries
has shown, where warfare and social dislocation have
often prevented the distribution of vaccines.
High-risk populations in rich countries will also need to be
targeted. Commercial sex workers, high-risk gay men,
haemophiliac people, injecting drug users, and children
born to HIV-positive mothers will need to be protected (or
partially protected) by these vaccines.
To ensure adequate manufacture and distribution of the
vaccine, we will need accurate measures of the numbers of
people in different regions that will require vaccination.
This will be a difficult task that will need to involve
governments and society.
How the vaccine will be used initially will be determined by
the rates of full and partial protection given by the early
generation of vaccines. If the early vaccines offer only
marginal protection, there may be reason to use these only
in high-risk groups and then wait for more successful
vaccines to be developed for use in lower-risk groups. The
same principle applies to any major side-effects: these will
be tolerated by and be acceptable to low-risk populations
only in the setting of very high predicted levels of
protection.
Timing of administration of HIV vaccines will be complex
and will need to take local factors into consideration.
Decisions will need to be made whether to include HIV
vaccines from birth in an expanded immunisation
programme or whether to wait until pre-adolescence (or
whether to immunise at both ages). Data on protection in
these two settings of vertical and sexual transmission will
help in these decisions.
SUBTYPES OF HIV
The number of described HIV subtypes increases constantly,
and their relevance to protective immunity remains
unresolved. The possibility of immune responses to specific
subtypes will continue to haunt HIV vaccinologists until
adequate data confirm or deny that cross-protection can
occur between subtypes. This matter will be difficult to deal
with once a successful vaccine is identified in one or more
geographical areas. For example, if a vaccine developed
from the subtype B virus was found to be successful in an
efficacy trial in the US, will this product then be seen as a
compulsory alternative to a placebo arm in another study
in a region in which subtype C is predominant? Because of
their regional distribution, HIV subtypes have assumed a
political and national importance, which could interfere
with important international trials of efficacy.
CONCLUSION
It is generally agreed that the development of an
affordable, appropriate, and effective HIV vaccine is within
reach - within 7 - 10 years. Vaccines are the only hope for
the control and possible elimination of HIV infection, as
was the case with smallpox and polio, which have been
fully or partially eliminated by global vaccination
programmes. How we distribute the vaccine will be a test
of our international ethics and humanitarian objectives,
and our generation will be judged by its success or failure
in making a vaccine and ensuring equitable access to it
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